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Abstract
Background Cyclosporine (CsA) remains an important
immunosuppressant for transplantation and for treatment of
autoimmune diseases. The most troublesome side effect of
CsA is renal injury. Acute CsA-induced nephrotoxicity is
characterized by reduced renal blood flow (RBF) and
glomerular filtration rate (GFR) due to afferent arteriole
vasoconstriction. Annexin A1 (ANXA1) is a potent anti-
inflammatory protein with protective effect in renal
ischemia/reperfusion injury. Here we study the effects of
ANXA1 treatment in an experimental model of acute CsA
nephrotoxicity.
Methods Salt-depleted rats were randomized to treatment
with VH (vehicles 1 mL/kg body weight/day), ANXA1
(Ac2-26 peptide 1 mg/kg body weight/day intraperitoneally),
CsA (20 mg/kg body weight/day subcutaneously) and
CsA ? ANXA1 (combination) for seven days. We
compared renal function and hemodynamics, renal histopa-
thology, renal tissue macrophage infiltration and renal
ANXA1 expression between the four groups.
Results CsA significantly impaired GFR and RBF, caused
tubular dilation and macrophage infiltration and increased
ANXA1 renal tissue expression. Treatment with ANXA1
attenuated CSA-induced hemodynamic changes, tubular
injury and macrophage infiltration.
Conclusion ANXA1 treatment attenuated renal hemo-
dynamic injury and inflammation in an acute CsA
nephrotoxicity model.
Keywords Acute renal injury  Annexin A1 
Cyclosporine nephrotoxicity  Immunosuppression 
Inflammation
Introduction
Cyclosporine A (CsA) is currently widely used in the
immunosuppressive protocol of solid organs and bone
marrow transplantation and in the treatment of several
autoimmune diseases [1]. The main side effect of CsA is
nephrotoxicity, which may cause functional and structural
injury [2]. Acute CsA nephrotoxicity is reversible and
characterized by impairments in the glomerular filtration
rate (GFR) and renal blood flow (RBF), and sublethal
tubular injury [3, 4].
The pathogenesis of CsA nephrotoxicity is multifactorial
with the participation of different systems, mediators and
cells [1], such as the renin–angiotensin–aldosterone system
[5], reactive oxygen species [6], transforming growth factor
[7] and macrophages [8]. Moreover, experimental studies
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have consistently demonstrated that acute CsA nephrotox-
icity is a consequence of imbalance between renal
vasoconstrictor and vasodilator systems, ultimately pro-
moting afferent arteriole vasoconstriction, renal ischemia
[4] and interstitial inflammation [8, 9].
The 37-kDa anti-inflammatory protein annexin A1
(ANXA1) is a glucocorticoid-regulated protein, originally
termed lipocortin [10]. ANXA1 is a member of the annexin
superfamily, composed of ubiquitous calcium-binding
proteins which are linked to membrane-related events and
cellular functions [11]. ANXA1 is highly expressed in the
cytosol of neutrophils [12], monocytes [13], eosinophils
[14] and epithelial cells [15]. Several studies have dem-
onstrated an important role for ANXA1 in acute [16] and
chronic [17] inflammation. In fact, ANXA1 inhibits
neutrophil and monocyte adhesion and migration through
inflamed postcapillary venule endothelium [12, 13],
decreases neutrophil recruitment in the inflamed tissue [18]
and accelerates apoptosis of polymorphonuclear cells [19].
There is much evidence demonstrating the importance and
protective role of ANXA1 in cardiac, mesenteric, cerebral
and renal ischemia/reperfusion (I/R) injury [20–24].
Recently, we demonstrated a structural protective role for
ANXA1 in an experimental model of acute tacrolimus
nephrotoxicity [25].
In the present study we used an experimental model of
acute CsA nephrotoxicity, which reproduces the functional
and structural changes caused by CsA in humans, to
investigate the effects of pharmacological treatment with
ANXA1 in CsA-induced renal injury. We described, for the
first time to the best of our knowledge, that CsA augments
ANXA1 expression in renal tissue and found a protective
role for ANXA1 in the hemodynamic changes and
inflammation caused by CsA.
Materials and methods
Animals
Male Munich–Wistar rats weighing 200–300 g (Sa˜o Jose´
do Rio Preto Medical School animal facility) were housed
in a temperature- and light-controlled environment. They
received a low salt diet [26] and tap water ad libitum.
Experiments were approved by the Sa˜o Jose´ do Rio Preto
Medical School Ethical Committee on Animal Experi-
mentation (Protocol 1,082/2008).
Experimental design and pharmacological treatment
After seven days on a low salt diet, rats were randomly
allocated to one of the four following groups (n = 12/
group): cyclosporine A (CsA, 20 mg/kg body weight/day
subcutaneously, Fujisawa, Japan) dissolved in ethanol and
olive oil [3], annexin A1 mimetic peptide (ANXA1, 1 mg/
kg body weight/day intraperitoneally with Ac2-26 peptide,
Ac-AMVSEFLKQAWFIENEEQEYVQTVK, Invitrogen,
USA) diluted in phosphate-buffered saline (PBS) [20],
CsA ? ANXA1, or identical volume of the respective
vehicles (VH) for seven days. Diet consumption was based
on pair feeding with CsA rats and weight was verified
daily. After seven days of treatment, rats were allocated for
GFR (n = 6/group) assessment or RBF (n = 6/group)
measurement. Renal tissue was collected for histological
evaluation at the end of each experiment.
Renal function studies
Animals were housed into metabolic cages for 24 h
(Nalgene Co., Rochester, NY, USA) after 7 days of treat-
ment for urinary volume collection (assessment of sodium,
potassium, creatinine and osmolality). Afterwards,
rats were anesthetized with intraperitoneal sodium pento-
barbital (50 mg/kg body weight) and placed on a
thermostatically controlled heated table (Braile Biome´dica,
Sa˜o Jose´ do Rio Preto, Brazil). Glomerular filtration rate
was measured by inulin clearance, as described previously
[26]. Results were mean of the three clearance periods and
glomerular filtration rate was calculated by the standard
formula.
Renal blood flow
After anesthesia, rats underwent renal hemodynamic
studies as previously described [25]. RBF measurements
were taken (T 106, Transonic Systems Inc., NY, USA)
during 40 min. Mean arterial blood pressure measurements
(Stoelting, Wood Dale, IL, USA) were taken concurrently,
and the renal vascular resistance was calculated by the
usual formula. At the end of the experiment, blood samples
(5 mL) were drawn to determine sodium, potassium, cre-
atinine and CsA blood levels.
Blood and urine analysis
Inulin was determined by the chemical anthrone method,
and urinary and serum creatinine were determined by the
Jaffe´ colorimetric method (ByoSystems BTS 310 spectro-
photometer, Barcelona, Spain). Urinary and serum sodium
and potassium concentrations were determined by an
electrolyte analyzer (9,180 Electrolyte Analyzer, AVL
Scientific Co., Rosweel, GA, USA). Urinary osmolality
was determined by freezing point (Osmette A, Precision
Systems, Natick, MA, USA). The fractional excretion of
sodium (FeNa) and potassium (FeK) were calculated by the
usual formulas.
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Radioimmunoassay
CsA blood levels were measured by a radioimmunoassay
kit (Diasorin, Stillwater, MN, USA).
Cytokine ELISA
Serum transforming growth factor (TGF)-b levels were
measured using an ELISA kit (OpEIA; BD Biosciences,
San Diego, CA, USA) according to the manufacturer’s
instructions.
Histopathological analyses
Renal fragments were fixed with 4% paraformaldehyde in
0.1 M sodium phosphate buffer (pH 7.4) for 24 h at 4C,
dehydrated and embedded in paraffin. Sections (2–4 lm)
were stained with hematoxylin–eosin, analyzed in five
fields (41,360 lm2 each) from the renal cortex using a
high-power objective (940) on a Zeiss-Axioskop 2 light
microscope (Carl Zeiss, Jena, Germany), and the area of
proximal tubules was measured using Axiovision software.
Immunohistochemistry
Renal sections (4 lm) underwent immunohistochemical
staining [25]. They were incubated overnight at 4C with
1:1,000 monoclonal mouse anti-rat-ED-1 (Serotec, Oxford,
UK) or 1:2,000 polyclonal rabbit anti-ANXA1 (Zymed
Laboratories, Cambridge, UK). Control sections were
obtained by replacing the primary antibodies with equiva-
lent concentrations of non-immune mouse or rabbit serum
(Sigma–Aldrich). Sections were then incubated with a
biotinylated secondary antibody, avidin-conjugated horse-
radish peroxidase, and enhanced with diaminobenzidine
chromogenic substrate (Dako, Carpinteria, CA, USA).
Renal fragments were counterstained with hematoxylin,
dehydrated and mounted. Quantification of macrophages in
the renal cortical tubulointerstitial area was performed with
Table 1 Renal functional parameters, cyclosporine blood levels and plasma TGF-b levels in vehicle (VH), annexin A1 (ANXA1), cyclosporine A
(CsA) and combination (CsA ? ANXA1) groups after 7 days of treatment
VH ANXA1 CsA CsA ? ANXA1
MABP (mmHg) 117 ± 4 119 ± 2 107 ± 1 117 ± 2
GFR (mL/min/100 g) 0.92 ± 0.08 0.96 ± 0.07 0.32 ± 0.05*** 0.39 ± 0.05***
SCr (mg/dL) 0.68 ± 0.06 0.61 ± 0.04 1.07 ± 0.08** 1.07 ± 0.05**
UV (lL/min) 10.8 ± 1.4 13.4 ± 2.1 10.5 ± 1.9 11.1 ± 0.9
UOsm (mOsm/Kg) 298 ± 23 224 ± 24 328 ± 40 299 ± 33
FeNa (%) 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00
FeK (%) 2.21 ± 0.22 2.74 ± 0.60 2.45 ± 0.47 2.46 ± 0.35
CsA (ng/mL) – – 2,480 ± 129 2,509 ± 176
TGF-b (pg/mL) – – 749 ± 223 436 ± 189
Data are mean ± SEM (n = 6 rats/group); MABP mean arterial blood pressure; GFR glomerular filtration rate; SCr serum creatinine; UV
urinary volume; UOsm urinary osmolality; Fe fractional excretion; Na sodium; K potassium; CsA blood trough level and serum TGF-b.
** p \ 0.01, *** p \ 0.001 versus VH and ANXA1
Fig. 1 Protective effects of annexin A1 (ANXA1) in acute cyclo-
sporine (CsA) nephrotoxicity. Rats on low-salt diet were treated with
VH (vehicles, 1 mL/kg body weight/day), ANXA1 (1 mg/kg body
weight/day intraperitoneally), CsA (20 mg/kg body weight/day
subcutaneously) and CsA ? ANXA1 for seven days. a Pharmacolog-
ical treatment with ANXA1 attenuated CsA-induced renal blood flow
(RBF) decrease and b renal vascular resistance (RVR) increase. Data
are mean ± SEM (n = 6 rats/group). *p \ 0.05 versus VH, ANXA1
and CsA ? ANXA1
Annexin A1 and cyclosporine nephrotoxicity 191
123
a high-power objective (940), counting cells in 25 fields
(41,360 lm2 each). Densitometric analysis for ANXA1
immunostaining was performed on an arbitrary scale
ranging from 0 to 255 by Axiovision software on a Zeiss-
Axioskop two-light microscope.
Statistical analysis
Results are mean ± SEM. Statistical evaluations of CsA and
TGF-b levels were performed using the two-tailed, unpaired
Student’s t test. Comparisons between all groups were per-
formed using one-way ANOVA followed by the Bonferroni
post-hoc test. In all cases, p \ 0.05 was taken as significant.
Results
Body weight and blood pressure
Body weight measurements demonstrated a significant
(p \ 0.05) weight loss in the CsA (-7.0 ± 2.6 g) and
CsA ? ANXA1 (-7.3 ± 2.1) groups compared to pro-
gressive body weight gain in VH (4.7 ± 1.1) and ANXA1
(5.7 ± 2.1) animals. Mean arterial blood pressure was
similar in all groups (Table 1).
Renal function analysis
CsA-treated animals had a significant decrease in GFR and
increase in SCr compared to VH and ANXA1 (p \ 0.001).
ANXA1 did not protect against CsA-induced GFR reduc-
tion and SCr increase (Table 1).
Twenty-four-hour urinary output was similar in all
groups. Fractional excretion of sodium (FeNa) and potas-
sium (FeK), and urinary osmolality (UOsm) were similar
and very low in all groups, reflecting the low salt diet
(Table 1).
CsA blood levels
CsA levels were similar in the CsA and CsA ? ANXA1
groups (Table 1).
Fig. 2 Annexin A1 partially
protected against cyclosporine
(CsA)-induced histological
changes in an acute CsA
nephrotoxicity model. a, b
Morphological analysis of renal
tissue from vehicle (VH) control
and annexin A1 (ANXA1)
groups showing typical
glomeruli (GR) and proximal
tubules (PT). c Micrograph
showing the renal cortex of a
salt-depleted rat given CsA,
20 mg/kg body weight/day
during one week, showing
tubular dilatation and
macrophage infiltration
(arrows). d ANXA1 gave
partial protection against tubular
injury. e Morphometric analysis
of renal proximal tubular
dilatation area. Data are
mean ± SEM (n = 6 rats/
group). ***p \ 0.001,
**p \ 0.01 versus VH and
ANXA1; #p \ 0.05 versus CsA.
Hematoxylin–eosin stain.
Bars = 20 lm
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TGF-b levels
TGF-b levels were undetectable in the VH and ANXA1
groups and elevated in CsA animals. There was a trend to
lower TGF-b in the CsA ? ANXA1 group, but it was not
statistically significant (Table 1).
Annexin A1 attenuated CsA-induced hemodynamic
changes
Treatment with CsA caused a significant decrease in the
renal blood flow and a significant increase in the renal
vascular resistance (RVR) compared to VH and ANXA1
(p \ 0.05). The administration of ANXA1 significantly
attenuated CsA-induced RBF reduction and RVR increase
(Fig. 1).
Annexin A1 attenuated CsA-induced histopathological
changes
Analysis of renal tissue from VH and ANXA1 animals
showed normal renal structures, without injury (Fig. 2a, b).
In contrast, CsA-treated animals showed acute tubule-
interstitial damage characterized by tubular dilatation and
infiltration of macrophages (Fig. 2c). ANXA1 administra-
tion conferred partial protection against CsA-induced
proximal tubule injury (Fig. 2d). These results were con-
firmed by morphometric analysis of cortical proximal
tubules (Fig. 2e).
CsA-induced macrophage influx
A large number of infiltrated macrophages were detected in
the cortical interstitial sections of CsA-treated rats at seven
days of treatment (Fig. 3a). ANXA1 treatment signifi-
cantly reduced CsA-induced renal macrophage infiltration
(Fig. 3b, c).
Cyclosporine increases annexin A1 expression
ANXA1 expression was detected in Bowman’s capsule
epithelium and in the macula densa in VH and ANXA1
animals (Fig. 4a, b), as well as in the medullary and
papillary collecting ducts (data not shown). CsA- and
CsA ? ANXA1-treated rats showed a significant aug-
mentation in ANXA1 expression in Bowman’s capsule
epithelium and in the macula densa (Fig. 4c, d). Figure 4e
reports the densitometric analysis of endogenous ANXA1
expression, demonstrating an exacerbated ANXA1
response associated with acute CsA nephrotoxicity.
Discussion
In this study we observed a partial protective effect
of ANXA1 against the acute hemodynamic changes
and tubular injury caused by CsA, paralleled by a partial
suppression of CsA-induced macrophage infiltration
and attenuation of CsA-induced tubular injury. We also
Fig. 3 Anti-migratory effect of
annexin A1 (ANXA1) in
monocyte/macrophage cell
infiltration detected by ED-1
immunostaining in cyclosporine
(CsA)-treated rats.
a Macrophage infiltration
(arrowheads) in CsA-treated
animals. b ANXA1 partially
prevented the macrophage
influx (arrowheads) in renal
tissue. c Quantitative analysis of
ED-1 positive cells in VH,
ANXA1, CsA and
CsA ? ANXA1 groups. Data
are mean ± SEM (n = 6 rats/
group). ***p \ 0.001;
**p \ 0.01 versus VH and
ANXA1; #p \ 0.05 versus CsA.
Hematoxylin counterstain.
Bars = 20 lm
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observed that CsA treatment augmented renal expression
of ANXA1, similar to that demonstrated in renal ischemia/
reperfusion models.
Afferent arteriole vasoconstriction is considered the
main mechanism responsible for the pathogenesis of
CsA-induced acute renal injury [1]. This event is mediated
by the imbalance of vasoactive factors, i.e. an increase of
vasoconstrictors (such as angiotensin II and endothelin)
and a decrease in vasodilators (such as prostaglandins and
nitric oxide) causing vasoconstriction [1, 4, 27]. ANXA1 is
an important endogenous anti-inflammatory mediator,
which is activated in response to cellular or tissue injury
[28, 29]. In recent years several studies have shown a
protective role for ANXA1 and its peptide Ac2-26 in car-
diac, mesenteric, cerebral and renal ischemia/reperfusion
(I/R) injury [20–23, 30].
A possible explanation for the attenuation in CsA-
induced hemodynamic and tubular injury in ANXA1-
treated animals is given by the observed reduction in the
number of macrophages infiltrating the renal tissue [26].
This early macrophage trafficking was consistently dem-
onstrated in previous studies of CsA nephrotoxicity [8, 9].
Previous results from our group have shown that clodronate-
induced macrophage depletion alleviates hemodynamic
changes in a model of CsA nephrotoxicity similar to that
used in the present study [26]. Activated macrophages
produce several substances with vasoactive properties and
are likely part of the mechanisms causing functional
changes in CsA nephrotoxicity [26]. It is noteworthy that
the protective effects of ANXA1 on CsA-induced RBF
impairment were not accompanied by a simultaneous
action on CsA-induced GFR fall. A possible explanation is
that the mechanisms promoting structural and hemody-
namic damage might be dissociated from those causing
functional changes in CsA nephrotoxicity [9, 31]. In the
cardiac I/R injury model, the protective effect of ANXA1
and its mimetic peptide is mediated by the formylated
peptide receptor (FPR) and is related to the reduction in
Fig. 4 Analysis of annexin A1
expression in renal tissue by
immunohistochemistry staining.
a, b Vehicle (VH) and annexin
A1 (ANXA1) groups
demonstrated modest staining
with anti-ANXA1 in Bowman’s
capsule epithelium and macula
densa (arrowheads). c, d CsA-
treated animals (CsA alone or
with ANXA1) showed intense
immunostaining of endogenous
ANXA1 (arrowheads). GR
glomeruli. e Mean optical
densitometry (MOD) analysis in
renal tissue immunostained for
ANXA1. Values are
mean ± SEM (n = 6 rats/
group). ***p \ 0.001 versus
VH and ANXA1. Hematoxylin
counterstain. Bars = 20 lm
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leukocyte transmigration, and IL-1b levels in the heart
[22]. Interestingly, CsA and ANXA1 are both ligands of
the formyl peptide receptor [32], which may interfere with
ANXA1 effects mediated by this same receptor and con-
sequently jeopardize a possible protective effect [33].
Only one week of CsA administration was sufficient to
increase plasma levels of TGF-b. A possible source for this
early over-production of TGF-b is the infiltrative macro-
phages. In fact, these inflammatory cells are a well-known
source of pro-fibrotic cytokines including TGF-b, which
has an important role in cellular proliferation [34] and
extracellular matrix deposition [35]. Even low doses of
CsA increased renal tissue expression of TGF-b [9] and
this cytokine accelerated matrix protein production in
chronic CsA nephrotoxicity [36]. ANXA1 has also been
show to regulate TGF-b expression, by enhancing Smad
signaling [37].
A novel result in the present study is the significant
CsA-induced increase in the renal expression of endoge-
nous ANXA1. Similarly, we have shown that salt-depleted
tacrolimus treatment augments renal ANXA1 expression
[25]. ANXA1 expression has previously been shown to
increase in response to glucocorticoids [38], inflammation
[28], heat or chemical cellular damage [39] and pro-
inflammatory cytokines [40]. Epithelial cells express a high
amount of ANXA1 and most of the properties of this anti-
inflammatory molecule, such as its anti-proliferative
action, inhibition of cell activation, and inhibition of both
phospholipase A2 activity and prostanoid generation [15]
are important components of the cell defense against I/R
injury [41]. In fact, ANXA1 expression is very different in
the normal and in the post-ischemic rat kidney. In a normal
kidney ANXA1 is mainly found in Bowman’s capsule
epithelium, macula densa and medullary and papillary
collecting ducts, with light staining at the thick ascending
limb. After ischemia/reperfusion, ANXA1 renal tissue
expression increases significantly [42], as observed in the
present study. These data suggest that endogenous ANXA1
increase might be an attempt to protect cell function and
structure against ischemia reperfusion injury [43]. In fact,
recent data from our group demonstrated that mimetic
peptide Ac2-26 treatment protected against ischemia/
reperfusion-induced renal structural and functional injury
regulating neutrophil and monocyte transmigration to
kidney tissue [24].
In conclusion, the present data provides in-vivo evidence
that ANXA1 mimetic peptide significantly attenuated CsA-
induced renal hemodynamic and tubular injury and kidney
macrophage infiltration in a rodent model of acute CsA
nephrotoxicity.
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